Skip to contentL
Lifecore Biomedical, Inc.
L
LFCRLifecore Biomedical, Inc. Q1 2022 · 10-Q
Revenue$41.63M$41.63M+83.6% vs Q1 2021 Net Income-$9.48M-$9.48MN/M vs Q1 2021 EPS Diluted-$0.32-$0.32N/M vs Q1 2021 Gross Profit$10,435,000+97.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lifecore Biomedical, Inc. · CIK 1005286 · Engraved from SEC EDGAR
Operating Cash Flow$831,000−95.2% Free Cash Flowderived-$7,082,000N/M Margins · derivedGross margin25.1%+1.7 pt vs Q1 2021
Operating margin-6.6%+40.2 pt vs Q1 2021
Net margin-22.8%+32.0 pt vs Q1 2021
ended Aug 29, 2021 · filed Oct 5, 2021 · 37 d after period end